Justin McCue - Tscan Therapeutics Chief Officer
| TCRX Stock | USD 4.52 0.26 6.10% |
Executive
Justin McCue is Chief Officer of Tscan Therapeutics
| Address | 830 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 857 399 9500 |
| Web | https://www.tscan.com |
Tscan Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2336) % which means that it has lost $0.2336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5592) %, meaning that it created substantial loss on money invested by shareholders. Tscan Therapeutics' management efficiency ratios could be used to measure how well Tscan Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. At this time, Tscan Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 3.8 M in 2024, whereas Total Assets are likely to drop slightly above 166.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MBA MD | Arrowhead Pharmaceuticals | 46 | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Aaron Tan | Arrowhead Pharmaceuticals | N/A | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Sarah Kiely | ProQR Therapeutics BV | N/A | |
| Michael MBA | Annexon | 53 | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Sean Proehl | Dermata Therapeutics | N/A | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Dr MPH | Dermata Therapeutics | 59 | |
| Rene Beukema | ProQR Therapeutics BV | 60 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Bruce MD | Arrowhead Pharmaceuticals | 70 | |
Management Performance
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.23 |
Tscan Therapeutics Leadership Team
Elected by the shareholders, the Tscan Therapeutics' board of directors comprises two types of representatives: Tscan Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tscan. The board's role is to monitor Tscan Therapeutics' management team and ensure that shareholders' interests are well served. Tscan Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tscan Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Justin McCue, Chief Officer | ||
| Jason CPA, CFO Treasurer | ||
| Leiden MBA, Principal Treasurer | ||
| David Southwell, Independent Director | ||
| Ray Lockard, VP Quality | ||
| Ray MBA, Senior Quality | ||
| Jim Murray, Senior Operations | ||
| Gavin MacBeath, Chief Officer | ||
| Stephen Elledge, CoFounder Board | ||
| Tomasz Kula, CoFounder Board | ||
| Ann Hargraves, Senior Resources | ||
| William MBA, Chief Officer | ||
| Jason Amello, Chief Officer | ||
| Cagan Gurer, Senior Discovery | ||
| Heather Savelle, Vice Relations | ||
| Debora MD, Chief Officer | ||
| Shrikanta MD, Senior Medicine | ||
| Brian JD, CFO VP | ||
| Zoran JD, Chief Secretary |
Tscan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tscan Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (31.10) % | ||||
| Current Valuation | 60.47 M | ||||
| Shares Outstanding | 49.09 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 93.37 % | ||||
| Number Of Shares Shorted | 2.16 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 1.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.